Australia markets close in 3 hours 47 minutes

Histogen Inc. (HSTO)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
1.0500+0.0200 (+1.94%)
At close: 04:00PM EST
1.0500 0.00 (0.00%)
After hours: 07:25PM EST

Histogen Inc.

10655 Sorrento Valley Road
Suite 200
San Diego, CA 92121
United States
858 526 3100
https://www.histogen.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees22

Key executives

NameTitlePayExercisedYear born
Dr. Steven J. Mento Ph.D.Exec. Chairman, Interim Pres & CEO335.4kN/A1952
Ms. Susan A. KnudsonExec. VP, CFO, Chief Compliance Officer & Corp. Sec.385.25kN/A1964
Dr. Gail K. Naughton Ph.D.Founder & Scientific AdvisorN/AN/A1956
Mr. Stephen Hill Jr.VP & ControllerN/AN/AN/A
Mr. Thomas L. HubkaDirector of Bus. Operations & Corp. Sec.N/AN/A1987
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.

Corporate governance

Histogen Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.